Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.

Inclisiran produced a mean LDL-C reduction of −46.5% at day 150 versus +1.4% with placebo and −11.2% with ezetimibe; the between-group differences were large and highly significant (inclisiran vs. placebo −47.9%, and vs. ezetimibe −35.4%; P < 0.0001 for both comparisons) [ 30 ].

also in 132,142 other papers

By contrast, reductions in circulating PCSK9 were large in both groups, and the between-group difference for PCSK9 did not reach statistical significance (P = 0.20).

also in 111,027 other papers